Becton Dickinson & Co. (NYSE:BDX) said it agreed to sell its BD Biosciences – Discovery Labware unit to Corning Inc. (NYSE:GLW) for about $730 million in cash.
becton dickinson
Device makers lack green initiative, report says | MassDevice.com On Call
MASSDEVICE ON CALL — A look at the top 10 medical device makers found that more than half had little to no environmental initiatives in place.
In a study conducted by Green Research, the companies with stainability initiatives were:
BD sets precedent with patent win over Abbott’s Therasense | Legal News
Medical Device Tax: Ten companies in line for a whack
The medical device tax set to take effect next year as part of the Affordable Care Act will see all medical device companies pay a 2.3% levy on U.S. sales. But the tax is likely to strike some companies a lot harder where it hurts the most: the bottom line.
Analyst: CRM market “bad as it’s ever been” | Wall Street Beat
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
Philips, B.D., Schein, Coloplast make the list for world’s most ethical | MassDevice.com On Call
MASSDEVICE ON CALL — The 2012 list of the world’s most ethical companies included a handful of medical device makers and group purchasing organizations, according to the research-based Ethisphere Institute.
Moody’s estimates med-tech tax impact
The 2.3% tax on revenues slated to go into effect next year for medical device makers could top $650 million for the med-tech companies covered by Moody’s Investor Services, according to a report by the ratings agency.
The tax will help slow EBIDTA growth rates for the med-tech sector to between 1% and 4% over the next year to 18 months, according to Moody’s, with organic growth rates of between 2% and 3% during that period.
GMI Ratings adds Boston Scientific to risky bet list | Wall Street Beat
A rating agency specializing in evaluating risky investments added Boston Scientific (NYSE:BSX) to its "Risk List," citing the ongoing fallout from its ill-starred Guidant buyout, its accounting and governance practices and how it pays its executives.
St. Jude and Stryker tie for most admired company for 2012 | MassDevice.com On Call
Moody’s raises Boston Scientific rating again | Wall Street Beat
AngioDynamics details $372M Navilyst buyout details | Wall Street Beat
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.